Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 208

1.

Intravenous ibandronate or sodium-fluoride--a 3.5 years study on bone density and fractures in Crohn's disease patients with osteoporosis.

Klaus J, Reinshagen M, Herdt K, Adler G, von Boyen GB, von Tirpitz C.

J Gastrointestin Liver Dis. 2011 Jun;20(2):141-8.

2.

Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D.

Klaus J, Reinshagen M, Herdt K, Schröter C, Adler G, von Boyen GB, von Tirpitz C.

World J Gastroenterol. 2011 Jan 21;17(3):334-42. doi: 10.3748/wjg.v17.i3.334.

3.

Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate.

von Tirpitz C, Klaus J, Steinkamp M, Hofbauer LC, Kratzer W, Mason R, Boehm BO, Adler G, Reinshagen M.

Aliment Pharmacol Ther. 2003 Mar 15;17(6):807-16.

4.

Increase of bone mineral density with sodium fluoride in patients with Crohn's disease.

von Tirpitz C, Klaus J, Brückel J, Rieber A, Scholer A, Adler G, Böhm BO, Reinshagen M.

Eur J Gastroenterol Hepatol. 2000 Jan;12(1):19-24.

PMID:
10656205
5.

Efficacy and safety of monthly ibandronate in men with low bone density.

Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G.

Bone. 2010 Apr;46(4):970-6. doi: 10.1016/j.bone.2009.12.034. Epub 2010 Jan 6.

PMID:
20060082
6.

Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.

Kreck S, Klaus J, Leidl R, von Tirpitz C, Konnopka A, Matschinger H, König HH.

Pharmacoeconomics. 2008;26(4):311-28.

PMID:
18370566
8.

Sustained-release sodium fluoride in the treatment of the elderly with established osteoporosis.

Rubin CD, Pak CY, Adams-Huet B, Genant HK, Li J, Rao DS.

Arch Intern Med. 2001 Oct 22;161(19):2325-33.

PMID:
11606148
9.

Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.

Bianchi G, Czerwinski E, Kenwright A, Burdeska A, Recker RR, Felsenberg D.

Osteoporos Int. 2012 Jun;23(6):1769-78. doi: 10.1007/s00198-011-1793-9.

PMID:
21975558
10.

Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.

Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F.

Osteoporos Int. 2003 Oct;14(10):801-7. Epub 2003 Aug 28.

PMID:
14610641
11.
12.

Slow-release sodium fluoride in the management of postmenopausal osteoporosis. A randomized controlled trial.

Pak CY, Sakhaee K, Piziak V, Peterson RD, Breslau NA, Boyd P, Poindexter JR, Herzog J, Heard-Sakhaee A, Haynes S, Adams-Huet B, Reisch JS.

Ann Intern Med. 1994 Apr 15;120(8):625-32.

PMID:
8135445
13.

The efficacy and safety of bisphosphonates for osteoporosis or osteopenia in Crohn's disease: a meta-analysis.

Guo Z, Wu R, Gong J, Zhu W, Li Y, Li N, Li J.

Dig Dis Sci. 2013 Apr;58(4):915-22. doi: 10.1007/s10620-012-2465-0. Epub 2012 Nov 20. Review.

PMID:
23179146
14.

Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease.

Stokkers PC, Deley M, Van Der Spek M, Verberne HJ, Van Deventer SJ, Hommes DW.

Scand J Gastroenterol. 2006 Feb;41(2):200-4.

PMID:
16484125
15.

High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease.

Klaus J, Armbrecht G, Steinkamp M, Brückel J, Rieber A, Adler G, Reinshagen M, Felsenberg D, von Tirpitz C.

Gut. 2002 Nov;51(5):654-8.

16.

Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.

Thiébaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, Schöter KH.

Am J Med. 1997 Oct;103(4):298-307.

PMID:
9382122
17.

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.

Clin Ther. 2009 Apr;31(4):751-61. doi: 10.1016/j.clinthera.2009.04.018.

PMID:
19446148
18.

Beyond daily dosing: clinical experience.

Cooper C.

Bone. 2006 Apr;38(4 Suppl 1):S13-7. Epub 2006 Mar 7. Review.

PMID:
16520105
19.

Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.

Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM.

Arthritis Rheum. 2006 Jun;54(6):1838-46.

20.

Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.

Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker RR.

J Rheumatol. 2008 Mar;35(3):488-97. Epub 2008 Feb 1.

PMID:
18260172
Items per page

Supplemental Content

Write to the Help Desk